Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Unity Biotechnology, Inc. UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer July 22, 2024 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates May 14, 2024 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting April 25, 2024 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME April 23, 2024 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates April 15, 2024 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss February 06, 2024 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME December 12, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates November 13, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds November 10, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration September 27, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates August 08, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME) June 21, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates May 09, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema April 24, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema April 23, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration March 27, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates March 15, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference February 28, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference February 15, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study February 09, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology Reports Granting of New Employment Inducement Award January 18, 2023 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates November 08, 2022 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema November 01, 2022 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema October 31, 2022 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today October 19, 2022 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye October 11, 2022 From Unity Biotechnology, Inc. Via GlobeNewswire Tickers UBX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.